Table 4. Literature based classification of PR- and PS-specific hubs.
| Pathways and programs | Hubs | |
|---|---|---|
| Wnt/β-catenin SP | TOP2A[112], EHMT2[113, 114], AXIN2[86, 87], FZD6[115], NLK[88, 116], and SENP2[117] | |
| P53 networks | HDAC1[90], SENP2[118], and CHD5[108, 119] | |
| Progression | CSC | PLCG1[95] |
| EMT programs | HDAC1, HDAC2[120], CHD5[108], PLCG1[95], GRM5[121], SPTAN1[122], and CACNA2D3[111] | |
| HIF-1α and VEGF production | PLCG[123] and GRM5[121] | |
| Chemotherapy | Resistance | PLCG2[124] and PLCG1[95] |
| Drug effects | GRM5[97] and SPTAN1[125] | |
| Cell cycle and DNA repair (proliferation) | NLK[88], AXIN2[126], TOP2A, HDAC1, HDAC2 [90], CEP72[127], BCL11A[84], BCL11B[85], POLA1, EHMT2[128], CHD5[108], GRM5[98], CAMK2A [129], GRAP2[130], and CACNA2D3[111] | |
| Apoptosis | HDAC2[90], BCL11B[81], SPTAN1[131], and CACNA2D3[111] | |
| Autophagy | EHMT2[132] | |
| Diverse | CKAP5[133], CEP72[101], UTY, GRIN2D[103], GRIN2B, and CACNA1S | |
Hubs were grouped based on their contributions to different pathways involved in cancer pathogenicity and chemotherapy-related events. Hubs which are not involved in significant pathways and programs, are included in the diverse group. PR- and PS-specific hubs are presented in bold and italic, respectively.
Abbreviations:
CSC: Cancer stem cell and EMT: Epithelial-mesenchymal transition.